BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22120844)

  • 1. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
    Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
    Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test.
    Alqahtani M; Grieu F; Carrello A; Amanuel B; Mashour M; Alattas R; Alsaleh K; Alsheikh A; Alqahtani S; Iacopetta B
    Asian Pac J Cancer Prev; 2016; 17(4):1917-23. PubMed ID: 27221876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
    Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
    Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the diagnosis and management of Lynch Syndrome in an Indigenous family living in a remote West Australian community.
    Schofield L; Goldblatt J; Iacopetta B
    Rural Remote Health; 2011; 11(4):1836. PubMed ID: 22188021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.
    Schofield L; Watson N; Grieu F; Li WQ; Zeps N; Harvey J; Stewart C; Abdo M; Goldblatt J; Iacopetta B
    Int J Cancer; 2009 Mar; 124(5):1097-102. PubMed ID: 19072991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
    Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
    Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
    Leenen CH; van Lier MG; van Doorn HC; van Leerdam ME; Kooi SG; de Waard J; Hoedemaeker RF; van den Ouweland AM; Hulspas SM; Dubbink HJ; Kuipers EJ; Wagner A; Dinjens WN; Steyerberg EW
    Gynecol Oncol; 2012 May; 125(2):414-20. PubMed ID: 22306203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.
    Bläker H; Haupt S; Morak M; Holinski-Feder E; Arnold A; Horst D; Sieber-Frank J; Seidler F; von Winterfeld M; Alwers E; Chang-Claude J; Brenner H; Roth W; Engel C; Löffler M; Möslein G; Schackert HK; Weitz J; Perne C; Aretz S; Hüneburg R; Schmiegel W; Vangala D; Rahner N; Steinke-Lange V; Heuveline V; von Knebel Doeberitz M; Ahadova A; Hoffmeister M; Kloor M;
    Int J Cancer; 2020 Nov; 147(10):2801-2810. PubMed ID: 32875553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.